Sotera Health Company (SHC) — Investment Analysis

Analyst: value-investing workflow | Date: 2026-06-06 | Exchange: NASDAQ | Currency: USD

Executive Summary

Three-sentence thesis. Sotera Health is the dominant player in an effectively-regulated global oligopoly for outsourced sterilization (Sterigenics), specialty lab testing (Nelson Labs), and Cobalt-60 supply (Nordion) — a genuinely wide-moat, mission-critical, recurring-revenue business with 20 consecutive years of revenue growth and 51% adjusted-EBITDA margins. The problem is not the business; it is the capital structure ($1.95B net debt, 3.2x net leverage) layered on top of a binary, potentially-catastrophic ethylene-oxide (EO) tort overhang that has already cost ~$510M in settlements (Willowbrook + Atlanta) and could re-escalate. At $15.62 the equity is roughly fairly valued to modestly rich on a levered-DCF basis, offering no margin of safety against the litigation tail — so despite David Einhorn's Q1-2026 conviction add, this is a WAIT, not a buy, until either the price falls to the low teens/high single digits or the EO appeals resolve favorably.

Metrics dashboard

1. The business

Sotera Health provides outsourced sterilization and related services that are deeply embedded in the medical-device, pharmaceutical, and food supply chains. Three segments (FY2025 revenue $1.164B):

1. Sterigenics (~64% of revenue, the engine). Contract sterilization via three modalities: ethylene oxide (EO, the chemical alternative for heat-sensitive devices), gamma irradiation (Cobalt-60), and X-ray/E-beam. FY2025 Sterigenics grew ~8% constant currency. ~50 facilities globally. Pricing power: +4.3–4.5% price every year (Q4-2025 and Q1-2026 transcripts).
2. Nordion (~17%). World's leading supplier of Cobalt-60, the radioactive isotope that powers gamma sterilization. Cobalt is "harvested" from nuclear power reactors on utility shutdown schedules — a multi-decade-relationship, supply-constrained niche. Segment income margins ~56–58%. Signed a cobalt development agreement with Westinghouse & PSEG and secured a 25-year Canadian Nuclear Safety Commission license renewal for Ottawa (the longest ever issued).
3. Nelson Labs (~19%). Outsourced microbiological and analytical lab testing plus Expert Advisory Services for regulated medical/pharma products. More fragmented and competitive than the other two; margins low-to-mid 30s. ~800–900 distinct tests.

Cross-business-unit (XBU) selling — bundling sterilization + testing for a single customer — grew revenue +9% in 2025, ahead of the company average. CEO Michael Petras (transitioning to Executive Chair May 2026; Alton Shader incoming CEO) repeatedly stresses ">70% of revenue is supported by multiyear contracts" with long-tenured customers.

2. Phase 1 — Risk analysis (inversion: what kills this?)

I weight the EO litigation heavily per the brief, because it is the one risk that can impair the equity independent of operating performance.

2.1 Ethylene-oxide tort litigation — the central, potentially existential risk

The fact pattern (from the FY2025 10-K legal-proceedings note):

• Willowbrook, Illinois (former facility). First trial (Sept 2022) produced a ~$363M plaintiff verdict; the second trial was a defense win. The company then settled over 880 claims for $408.0 million (finalized June 2023), plus an additional $30.9M (97 claims, Sept 2025) and $34.0M (129 claims, Feb 2026) — cumulative Willowbrook settlements of roughly $473M.
• Atlanta, Georgia (Cobb County). $35M to resolve 79 claims (finalized Jan 2024). But ~450 personal-injury claims and ~305 property-devaluation claims related to the Atlanta facility remain pending in Cobb County, plus a customer-employee exposure suit.
• New Mexico public-nuisance case set for trial ~July 2026; an Illinois (Willowbrook-area) matter referenced as a subsequent event.

The crucial 2026 development (Q1-2026 transcript, management summary): Eight bellwether personal-injury cases were funneled into Phase 1 (general causation) and Phase 2 (specific causation) science proceedings. In October 2025 the court dismissed 3 cases on specific causation; on March 30, 2026 the Georgia State Court dismissed the remaining 5 bellwethers because plaintiffs could not prove general causation. All eight bellwethers are now dismissed (subject to appeal). Management argues the rejection of plaintiffs' general-causation theories "is a critical issue common to all other personal injury cases."

Probability x impact framing (my own estimate):

The 10-K itself is unusually candid: an adverse judgment could require posting "an appellate bond of a significant amount" and "there is no assurance that our subsidiaries or the Company will meet the requirements to provide an appellate bond." That is the tail that prevents a clean buy. Note also that EO is not a Sotera-specific problem — it is an industry-wide regulatory and tort theme (competitors face similar suits), and the science (IARC classifies EO as a carcinogen) is genuinely contested in court.

2.2 Financial leverage

Net debt $1.95B on ~$636M 2026E adjusted EBITDA = 3.2x, down from 3.7x in 2024 — improving, but still meaningful. The term loan is ~$1.4B floating (Term SOFR); the 10-K discloses a 1% rate move = ~$10.2M annual interest. 2025 interest expense was $156M; 2026 guide $135–145M after a 75bps repricing and $86M paydown. Interest coverage (adj EBITDA / interest) is ~4x — adequate but not fortress. Leverage is the multiplier that turns a fairly-valued enterprise into a thin, volatile equity.

2.3 Regulatory (EPA NESHAP)

The EPA's tightened EO emissions rule (NESHAP) is a double-edged sword. Cost: ~$200M of facility enhancements at Sterigenics ("vast majority complete in 2026"). Opportunity: tighter rules pressure smaller/in-house sterilizers, driving outsourcing to Sotera (one "meaningful, not outsized" customer is converting, ramping late 2026–2028). A new, slightly-softer proposed rule injects uncertainty but management is executing to the stricter existing rule. Net: manageable and arguably moat-widening.

2.4 Disruption / competition

Sterilization is a slow-moving, regulated physical-infrastructure business — low disruption risk. Nelson Labs is the most competitive (fragmented). The principal "disruption" risk is regulatory pressure on EO itself pushing the industry toward X-ray/E-beam, which Sotera is investing in (new X-ray greenfield online H2 2026) — so it is a participant in, not a victim of, that shift.

2.5 Management / governance / ownership

Founder-era CEO Petras (since 2016) steps up to Executive Chair; Alton Shader (Viant Medical, Hillrom, Baxter) becomes CEO May 2026 via a board-led succession. Private-equity sponsors (GTCR, Warburg Pincus) have steadily sold down — public float rose from 80% (2025) to 90% (March 2026). Continued PE secondary sales are an ongoing technical supply overhang on the stock, though they also improve float/index eligibility. Insider ownership is low (2.4% per overview), partially offset by Petras describing himself as "a meaningful investor."

3. Phase 2 — Financial analysis

3.1 Quality of earnings and returns

GAAP net income is noisy because of (a) settlement charges and (b) heavy interest and D&A from the PE-era capital structure and purchase-accounting intangibles. The cleaner signals are adjusted EBITDA margin (~51%, expanding 118bps in 2025) and pricing power (+4%/yr), both consistent with a genuine moat.

Returns on capital (my calc, 2025):

• Adjusted EBIT ~ $457M; NOPAT @28% ~ $329M.
• Reported invested capital (debt + equity - cash) ~ $2,560M -> ROIC ~ 12.9%.
• The reported figure is depressed by $1.1B goodwill + $0.3B intangibles from the 2015 PE buyout. On tangible invested capital (~$1.17B), ROIC ~ 28% — strong, and the more economically meaningful figure for a business whose moat is physical facilities + regulatory licenses, not the price a sponsor paid.
• ROIC of ~13% (reported) comfortably exceeds a ~9–10% WACC; on tangible capital the spread is wide. This is a value-creating business.
• Reported ROE (overview TTM) ~22.7%; 5-yr average ROE is distorted negative by the 2022 settlement year.

3.2 Owner earnings / FCF

• 2025 operating cash flow $287.2M; capex $138M; simple FCF $149M; management's "adjusted FCF" (adding back legal settlement cash) was $210M.
• Near-term FCF is suppressed by elevated capex ($175–225M guided for 2026) for the X-ray greenfield, EO upgrades, and Cobalt-60 development — much of which is non-recurring (the $200M EO program largely completes in 2026).
• Normalized maintenance capex once those programs finish is closer to D&A (~$130M), implying normalized FCF stepping toward $280–320M as capex normalizes and deleveraging cuts interest. Management's 2025–2027 cumulative adjusted-FCF target is $500–600M ($210M booked in year one).
• Owner-earnings yield on EV ~ 3%; on market cap ~ 4–6% normalized. Decent, not cheap.

3.3 My valuation (own work, no analyst inputs)

I triangulate three methods. The central tension: the enterprise is reasonably valued, but the equity is a thin, levered slice, so equity value is hugely sensitive to the EBITDA multiple and the FCF path.

(a) Levered DCF on FCF to equity (9.5% discount, 2.5% terminal; FCF path $180->210->260->300->330M as capex normalizes and interest falls):

• Base equity value ~ $7.1/share. Sensitivity: $4.75 (10.5% disc / 2.0% g) to $10.83 (8.5% disc / 3.0% g). Bull (insourcing wins, faster delever) ~ $12; bear (litigation + sustained high capex) ~ $1–3.
• The DCF is harsh precisely because $1.95B of net debt and ~$140M/yr interest sit ahead of the equity.

(b) EV/EBITDA multiple on 2026E adjusted EBITDA $636.5M, less $1.95B net debt:

• 10x -> $15.2/sh; 11x -> $17.4/sh; 12x -> $19.6/sh.
• Quality sterilization/lab peers (e.g., STERIS) trade ~14–18x EBITDA; SHC's discount to ~10x reflects leverage + litigation. A "clean" SHC arguably deserves 12–13x; the discount is the market correctly pricing the tail.

(c) Normalized levered-FCF yield: $280M normalized FCF at a 6–7% equity FCF yield -> $13.8–16.1/sh.

Synthesis. Weighting the DCF (captures leverage drag) against the multiple/yield methods (capture quality), I arrive at a fair value range of ~$12–16, with a base around $14. The current $15.62 sits at the upper end — i.e., the market is paying for the quality and assuming a benign litigation outcome, leaving no margin of safety.

Litigation adjustment: a base reserve of $80M ($0.28/sh) is minor; an adverse-appeal tail of $300–400M (~$1.05–1.40/sh, before bonding/liquidity strain) is the real risk and is not discountable to a point estimate — it is binary.

3.4 Relative valuation sanity check

At 10.2x EV/EBITDA and ~16x forward adjusted EPS for a 51%-margin oligopoly growing mid-single-digits, SHC is neither obviously cheap nor expensive on the enterprise. The GAAP P/E of ~38x is misleading (interest + D&A + tax drag); the forward adjusted P/E of ~16x is the fairer lens and is roughly market-multiple for a slower grower — reasonable, not a bargain.

4. Phase 3 — Moat analysis

Moat sources (Wide, durable 15–20+ years):

1. Regulatory / switching costs (the core moat). A sterilization facility is validated into a medical device's FDA submission. Re-validating to a new provider/modality is expensive, slow, and risk-laden for the device maker — so customers stay for decades. >70% of revenue under multiyear contracts. This is a textbook switching-cost + regulatory moat.
2. Scale / network. ~50 global facilities let multinational customers contract on a single global basis across all modalities and geographies — a one-stop position smaller rivals cannot match.
3. Cobalt-60 supply control (Nordion). Multi-decade relationships with nuclear utilities and ultra-long-dated licenses (25-yr Ottawa renewal) create a near-irreplaceable supply position in gamma's critical input.
4. Pricing power, measured. +4%/yr price increases stick year after year across cycles — the cleanest quantitative proof of moat.

Durability test. 20 consecutive years of revenue growth "across multiple economic cycles" (management) and through COVID. The demand is non-discretionary (you cannot sell an unsterilized implant). The main moat threat is EO-specific regulation/litigation, which Sotera is mitigating by investing in alternative modalities — so the moat is stable-to-widening on the business, even as the legal overhang is the offsetting negative. Trend: stable.

5. Phase 4 — Synthesis

5.1 Expected-return tree (5-year, illustrative)

Probability-weighted ~$17–18 in 5 years vs $15.62 today is a low-single-digit IRR with a fat left tail — insufficient compensation for the binary risk and the leverage. The asymmetry only becomes attractive at a lower entry.

5.2 Position sizing & entry

• Strong Buy ~ $9.50 (~9x EV/EBITDA-equivalent / forward P/E ~10x): a price that prices in a meaningful litigation tail and demands the deleveraging optionality for free. ~40% below current.
• Accumulate ~ $11.50–12.00 (15–25% below fair-value midpoint): start building a position with a real margin of safety.
• Target allocation if/when in range: 2–3% (capped by leverage + binary-risk).
• Current price offers no margin of safety -> no action.

5.3 The Einhorn signal — honored, but not decisive

David Einhorn (Greenlight) increased his SHC position +348% in Q1 2026 — a strong vote from a disciplined value investor, and the timing (right around the favorable March-30 bellwether dismissals) suggests he is playing the litigation-overhang-lifting thesis with cheap optionality on deleveraging. I respect the call and the catalyst read. But Greenlight's cost basis and concentration tolerance differ from a margin-of-safety mandate: at $15.62 the equity is already at the top of my intrinsic range, so following him here means buying quality at a fair-to-rich price with a binary tail. I would rather wait for the price to come to me or for the appeals to de-risk. Conviction add noted; my verdict remains WAIT.

5.4 Monitoring triggers (what flips this to BUY)

• **Price < $12** (margin of safety appears) -> Accumulate; **< $9.50** -> Strong Buy.
• EO appeals affirm bellwether dismissals and/or Cobb County pending claims settle/dismiss at de-minimis values -> overhang lifts, re-rate.
• **Net leverage < 2.5x** with continued FCF growth -> equity de-risks structurally.
• New CEO Shader sustains pricing/margin discipline and the 2025–2027 FCF target.
• Insourcing-conversion pipeline materializes into multiple signed wins (NESHAP tailwind).

5.5 Monitoring triggers (what confirms a REJECT/sell)

• Adverse New Mexico public-nuisance or appellate ruling forcing a large appellate bond.
• Net leverage re-expanding (debt-funded M&A or settlement cash).
• Pricing power eroding below ~3%/yr (moat-crack signal).

6. Risk register

Primary-source citations

• SEC Form 10-K FY2025 (filed 2026-02-24, CIK 0001822479): legal proceedings note (Willowbrook $408M+$30.9M+$34.0M; Atlanta $35M; ~450 PI + 305 property claims pending Cobb County; appellate-bond risk language); debt note (Term Loans, SOFR sensitivity); risk factors (EO/Co-60).
• SEC Form 10-K FY2024 and FY2023 (filed 2025-02-27, 2024-02-27): multi-year comparatives.
• SHC Q1 2026 earnings call transcript (AlphaVantage): bellwether dismissals 03/30/2026, CEO succession, reaffirmed 2026 guide.
• SHC Q4/FY2025 earnings call transcript (AlphaVantage): FY2025 results, 51% EBITDA margin, $210M adjusted FCF, 3.2x leverage, X-ray greenfield economics.
• AlphaVantage INCOME_STATEMENT / BALANCE_SHEET / CASH_FLOW / COMPANY_OVERVIEW (SHC).
• AlphaVantage TIME_SERIES_DAILY_ADJUSTED (SHC), 2020-11-20 to 2026-06-05.

All valuation work is independent; no sell-side price targets or ratings were used as inputs.